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Abstract
Introduction: The determination of toxic elements in the biological samples of
human beings is an important clinical procedure. This study was performed to
investigate the prevalence of abnormal blood contents of 2 trace elements (TEs),
aluminum (Al),and lead (Pb) in hemodialysis (HD) patients and to analyze their
relationship with the medications, such as CaCO3, Ca acetate, 1,25-dihydroxy
vit. D3, and erythropoietin (EPO), as well as hematocrit level.
Material and methods: We included 43 patients on maintenance HD and they
had continued the previously mentioned medications for at least 3 months. None
of the patients were on Al containing phosphate binding agents. 
Results: Serum aluminum and lead levels were significantly increased than in
the healthy controls, but levels of both of them were far below toxic values.
Male patients had higher mean levels of lead than did females. A strong positive
correlation was found between serum Al and serum Pb levels among patients
(r = 0.075, p = 0.0001).The serum level of Pb was positively correlated  with the
serum albumin in HD patients (r = 0.45, p = 0.03). Both serum aluminium and
lead levels positively correlated with the EPO dose taken by the patients 
(r = 0.77, p = 0.0001 and r = 0.67, p = 0.0001 respectively).
Conclusions: The blood level of trace metals of these HD patients was not related
to their medications except for the EPO dose. However, caution must be
exercised in interpreting this result as dose and duration of medication may
play an important role. Al and Pb over load may be considered from the causes
of inadequate response to epoetin therapy.
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Introduction
Despite recent improvements in dialyser design and advances in dialysis
technique, many uraemic symptoms remain unresolved by maintenance
dialysis. Some of these clinical symptoms are attributed to inadequate
dialysis or so-called uraemic toxins. However, the abnormal metabolism
of trace elements (TEs) in chronic dialysis patients, a frequently overlooked
fact, may be one of the contributing factors to the patients' clinical
discomforts [1, 2].
Trace metal burden in chronic renal insufficiency and dialysis patients has
been studied. Those studies, however, are somewhat incomplete owing to
small sample sizes, contradictory results, and different analytic techniques [3].Arch Med Sci 3, June / 2010 421
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Aluminium (Al) is a well known risk factor for
increased morbidity and mortality among
haemodialysis (HD) patients all over the world [4].
The well-described long-term effects of sustained
exposure to aluminium in patients with end-stage
renal disease (ESRD) are a result of uptake and
storage of aluminium, leading to cellular toxicity.
Accumulation of aluminium in the tissues of
patients on chronic haemodialysis may cause
dysfunction of some organs [5]. In 1976, Aifrey 
et al. [6] attributed the previously described syndrome
of dialysis dementia to an increased aluminium
concentration in the brain of their encephalopathic
patients. Subsequently, the association between
increased aluminium concentrations in the
cerebrum and dialysis encephalopathy seems to
have been reasonably well established [7]. In 1971,
Parsons et al. [8] demonstrated abnormally high
aluminium concentrations in the bone of patients
on chronic HD. More direct evidence for a causal
association between dialysis osteomalacia and
aluminium accumulation in bone has been provided
by experimental and human studies of bone
aluminium concentrations and bone histology [9].
Microcytic hypochromic anaemia has been
reported in patients with excessive aluminium
accumulation [10]. Serum aluminium concentrations
may fluctuate as a result of oral [11] or parenteral
[12, 13] administration of aluminium-containing
compounds. Most of the reports on aluminium
toxicity in HD patients have appeared from western
countries. Reports from the Arab world on the
prevalence of toxicity, or on the measures adopted
to contain this, are scanty [14].
Among the general population, it has been
assumed that an average of 150 g to 250 g of lead
(Pb) is ingested through food each day, 5-10% of
which is absorbed [15]. The other sources for lead
poisoning may be lead-soldered kettles, cans, and
lead-glazed pottery, which release lead when acidic
fluids are stored or cooked in them [15]. The lead
in blood is equilibrated with that of lead in tissues,
including many potential target organs such as the
brain and kidney. The kinetic model of lead in the
body is not defined well, but usually it consists of
two pools: in the blood and in the skeleton, which
may be divided further into labile and deep pools
[16]. The kidney is the main organ excreting lead
from the pool. Thus, lead burdens have a tendency
to be accumulated in patients with renal failure [17].
The skeleton acts as a reservoir of lead, and it
may be mobilized by physiological and pathological
states including pregnancy, lactation, and
osteoporosis [18, 19]. In patients with end stage
renal disease (ESRD), hyperparathyroidism,
abnormal vitamin D metabolism, and consequent
osteoporosis have frequently been observed [20].
Taken together with the lack of renal excretion and
stimulated bone resorption, the blood level of lead
seems to increase in ESRD and may aggravate
uraemic symptoms such as peripheral neuropathy
and anaemia.
The classic clinical manifestations of industrial
lead poisoning include colic, anaemia, peripheral
neuropathy, encephalopathy, renal impairment,
hypertension, and reproductive disability [21]. More
recently, recognition has become widespread that,
in addition to its clinically evident toxicity, lead also
causes a spectrum of adverse effects at levels of
exposure insufficient to produce obvious signs and
symptoms. The premise underlying this recognition
is that there exist asymptotic, subclinical
counterparts. Thus, clinically obvious manifestations
of lead poisoning such as anaemia, peripheral
neuropathy, and renal failure lie at the upper end
of the range of toxicity, while such covert effects
as impaired synthesis of haem, altered excretion of
uric acid, and slowed nerve conduction are their
subclinical correlates [22]. Although many
investigators have described increased blood levels
of lead in renal failure patients [23-26], the role of
lead on the clinical characteristics remains to be
elucidated.
Multiple drugs are frequently used for the
underlying diseases and uraemic complications. The
possibility of trace metal contamination of various
medications and the effect of medications on the
metabolism of trace metals are still unknown.
The present study was undertaken to investigate
the prevalence and the clinical correlation of
aluminium and lead abnormalities among ESRD
patients receiving maintenance haemodialysis, and
to analyse their relationship with frequently used
drugs such as erythropoietin (EPO), Ca carbonate
(CaCO3), Ca acetate, and Rocaltrol (1,25-(OH)2 vit. D3).
Material and methods
Forty-three children with ESRD undergoing
haemodialysis, at the haemodialysis unit of the
Centre of Paediatric Nephrology and Transplantation
(CPNT), Children's Hospital, Cairo University were
investigated. The study was conducted from
October 2008 to March 2009. Detailed patient
characteristics are given in Table I. All patients were
dialysed using a polysulfone dialyser, with
bicarbonate dialysate, using a blood flow rate of
80-150 ml/min and a dialysate flow rate of 500
ml/min. Each subject was dialysed 3 times per week
using polysulfone membranes. The dialysate fluids
were prepared from concentrated salt solutions and
from bicarbonate powder in sealed containers. As
recommended by the FDA, the water purification
system combines a double softener with a double
granular charcoal filter and a double reverse
osmosis module in series. The accepted limit for
aluminium contamination in the ultrapure water422 Arch Med Sci 3, June / 2010
was 0.01 ppm. According to the guidelines of the
American Association of Medical Instruments [27]
and European Pharmacopoeia [28], appropriate
laboratory methods were chosen to detect bacteria
(upper limit for bacterial growth < 100 colony
forming units per millilitre in dialysate) as well as
endotoxins (upper limit 0.25 EU/ml) and other
bacteria-derived substances (whole blood cytokine
induction assay). Inclusion criteria included children
on regular HD treatment for not less than 
4 months, using bicarbonate dialysate and free
from apparent acute illness. Patients with severe
illness or acute medical events were excluded.
Patients had taken routine medications in
a dialysis unit for at least 3 months, such as
phosphate-binding agents calcium carbonate 
(35 patients [81.40%], 500 mg\tab Ca 0.2 g, 10 mEq)
at a dose of 500-4000 mg/day, or calcium acetate
(8 patients [18.60%], 500 mg\tab, Ca 0.2 g, 10 mEq)
at a dose of 1500-2000 mg/day. Patients with
parathormone (PTH) level greater than 100 pg\ml
or hypocalcaemia received daily Rocaltrol (38
patients [88.37%]), at a dose of 0.25-2 µg/day.
Medication compliance was checked by question  -
naires and re-enforced at each dialysis unit. 
An EPO 750-9000 IU/week subcutaneous injection
was administered to maintain haematocrit between
28% and 31%. None of the patients received Al
containing phosphate-binding agents. Forty-three
healthy, age- and gender-matched children (28
[65.12%] male, 15 [34.88%] female; average age 10.5
±3.32 years, range 3-17 years) (NS) were recruited
from the paediatric clinic of the National Research
Centre to serve as controls. Written consent was
obtained from the parents of each patient.
Clinical and biochemical tests
All the patients were subjected to full history
taking and thorough clinical examination. Haemo  -
globin (Hb), haematocrit (HCT), albumin (ALB),
serum calcium (Ca), serum phosphorous (Ph), blood
urea nitrogen (BUN) and creatinine were measured
for all patients using an automatic biochemistry
analyser.
Blood sample collection
A peripheral blood sample was obtained prior to
the haemodialysis session from the venous part of
the arteriovenous fistula using a specially selected
disposable plastic syringe. The specimen was
transferred to a plastic tube and then immediate
centrifugation was done for 10 min at 5,000 rpm at
4°C. The centrifuged serum was transferred into
sterile tubes. All samples were stored in a refri  -
gerator at 4°C until the time of analysis.
Determination of serum concentration 
of aluminium and lead
Trace lead and Al determination was carried out
using a graphite furnace Atomic Absorption
Spectrometer (Varian Spectr. AA 220) equipped with
a graphite furnace auto-sampler (GTA-110). The
spectral lines used for Pb and Al determination
were 283.3 nm and 396.2 nm respectively.
Background correction was carried out using
a deuterium arc lamp.
Before Pb measurement, samples were diluted
five times with a mixture of Triton X-100 (0.2%) and
Dow Corning Antifoam B (0.2%) then a portion of
the sample was introduced into the graphite
atomization tube. For Al measurements, samples
were diluted 1 : 1 with a mixture of Triton X-100
(0.2%) and Dow Corning Antifoam B (0.2%) then
a portion of the sample was atomized.
For both elements the standard addition
technique was applied to construct the analytical
calibration curve in which an increasing volume of
Pb or Al solution was added to the sample to give
similar atomization behaviour of both samples and
standards. A volume of the standard solution 
(100 µg/l for Pb and 20 µg/l for Al) was added to
give final concentrations of the added lead of 
Variable Controls (n = 43) Patients (n = 43) Value of p
Age [years] 10.5 ±3.32 11 ±3.36 NS
Male/female [%] 28/15 (65.12%/34.88%) 22/21 (51.16%/48.84%) NS
Systolic blood pressure [mmHg] 95.44 ±9.81 123.18 ±14.60 < 0.0001*
Diastolic blood pressure [mmHg] 65.67 ±10.24 82.73 ±12.41 < 0.001*
Antihypertensive medication [%] – 33 (76.74%)
Duration of dialysis [years] 2.91 ±1.44
Dialyser SA (range) 0.7-1.3
Kt/V 1.64 ±0.38
Data are means ± SD, number (%) or range as applicable. Significance was estimated using independent t-test, *p was significant < 0.01, 
SA – surface area, Kt/V – adequacy of dialysis
Table I. Comparison of general characteristics between controls and patients with end stage renal disease
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10, 20, 30 and 40 µg/l and Al of 2, 4 and 8 µg/l
respectively. Palladium solution (1000 µg/ml) was
used as a matrix modifier from which a volume of
10 µl was added before every sample or standard
measurement of Pb. A portion of sample (20 µl) was
added to the atomization tube then the heating
programme started. The calibration curve was
found to be linear over the used calibration range.
The temperature programme used for atomization
included maximum drying temperatures of 120°C,
ashing temperatures of 480°C and 1100°C, and
atomization temperatures of 2500°C and 2500°C
for Pb and Al respectively [29].
Determination of intact parathyroid 
hormone in serum by chemiluminescent 
immunometric assay
IMMULITE/IMMULITE 1000 is a solid phase
chemiluminescent immunometric assay (supplied
by SIEMENS Medical Solution Diagnostics) [30].
Statistical analysis
Statistical Package for the Social Sciences (SPSS)
version 11.0 was used for analysis of data. Matching
was done by using two main approaches: pair
(individual) matching and frequency matching. Data
were summarized as mean ± SD, range or
percentage. Comparisons of continuous variables
between the two groups were performed by
independent-samples t test where appropriate.
Pearson's analysis was performed to correlate the
serum concentration of aluminium and lead with
the individual variables. Multiple linear regression
analysis with backward method was performed to
determine the contribution of various factors as
independent variables or covariates to aluminium
or lead as the dependent variables. A p value of 
< 0.05 was considered significant.
Results
Comparison of general characteristics
between controls and patients with 
end stage renal disease
There were significant differences in systolic (123.18
±14.60 mmHg vs. 95.44 ±9.81 mmHg, p < 0.0001) and
diastolic blood pressures (82.73 ±12.41 mmHg vs. 61.65
±10.24 mmHg, p < 0.001) between the HD patients
and the controls. Thirty-three patients have had
antihypertensive medication Table I.
Comparison of basic biochemical data 
between controls and patients with end
stage renal disease
Moderate anaemia was present in the
haemodialysis patients when compared to the
controls (Table II). Haemoglobin was 9.72 ±1.47
mg/dl vs. 14.23 ±1.50 mg/dl in the controls 
(p < 0.001). Serum calcium was significantly lower
in the patients than in the controls (10.27 ±1.68
mg/dl vs. 10.91 ±0.40 mg/dl), and hyper  pho  -
sphataemia (5.04 ±3.42 mg/dl vs. 3.9 ±0.58 mg/dl)
was present in the HD patients. There was
a significant statistical difference between the HD
patients and the controls as regards the
parathormone (PTH) level (140.62 ±90.32 pg/ml vs.
1.65 ±0.65 pg/ml, p < 0.0001).
Serum aluminium levels were significantly higher
in the ESRD patients than in the healthy controls
(18.43 ±4.37 µg/l vs. 6.50±1.60 µg/l, p < 0.001)
(Figure 1). The ESRD patients had higher blood lead
levels than in the controls (34.31 ±9.70 µg/l vs. 5.36
±1.77 µg/l, p < 0.0001) (Figure 2).
The blood levels of both aluminium and lead
were far below their toxic values (> 100 µg/l for Al
level, and > 60 µg/l for lead level) [31]. Male patients
had higher mean levels of lead than did females
(38.50 ±7.61 µg/l vs. 30.13 ±10.05 µg/l, p < 0.04)
(Table III). There were no statistical differences
between males and females with regard to age or
dialysis duration.
Correlation between aluminium and lead
levels among haemodialysis patients
A strong positive correlation was found between
serum Al and serum Pb levels among the HD
patients (r = 0.075, p = 0.0001) (Table IV).
Correlation of aluminium and lead levels with 
different variables in haemodialysis patients
A positive linear correlation was revealed between
the serum lead levels and the age of HD patients 
Variable Controls Patients Value of p
Haemoglobin [mg/dl] 14.23 ±1.50 9.72 ±1.47 < 0.001**
Serum calcium [mg/dl] 10.91 ±0.40 10.27 ±1.68 < 0.05*
Serum phosphorous [mg/dl] 3.90 ±0.58 5.04 ±3.42 < 0.001**
Serum parathormone [pg/ml] 1.65 ±0.65 140.62 ±90.32 < 0.0001**
Data are reported as means ± SD. Significance was estimated using independent t-test, *p was significant if < 0.05 or **p < 0.01
Table II. Comparison of basic biochemical data between controls and patients with end stage renal disease
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(r = 0.50, p = 0.003), but not between the serum
levels and the dialysis duration (r = 0.29, p = NS).
Another positive finding was that serum lead levels
increased with increasing dialyser surface area 
(r = 0.54, p = 0.01). A positive correlation was found
between the serum lead levels and the serum
albumin in HD patients (r = 0.45, p = 0.03). Serum
parathyroid hormone level correlated positively with
the serum aluminium (Figure 3) and the serum lead
levels (Figure 4) among HD patients (r  = 0.78,
p = 0.0001, and r = 0.60, p = 0.0001, respectively), but
was not correlated with the age or with the dialysis
duration. A significant positive correlation was
revealed between the serum aluminium levels and
the EPO dose taken by the patients (r  = 0.77,
p = 0.0001) (Figure 5). Also the serum level of lead was
correlated positively with the EPO dose received by the
patients (r = 0.67, p = 0.0001) (Figure 6, Table V). 
Multiple linear regression analysis comparing
the correlation of aluminium and lead levels
with individual variables in serum 
of haemodialysis patients
On correlating the Al and lead values and other
individual variables by multiple linear regression
analysis, PTH and EPO dosage were variables that
were independently associated with elevated Al
values (p < 0.05). Serum concentration of lead was
independently associated with age, PTH level and EPO
dosage taken by the patients (p < 0.05) (Table VI).
There were statistical correlations between the
erythropoietin dose used and the haemoglobin value,
and haematocrit level in these patients (r = 0.45,
p = 0.03, and r = 0.47, p = 0.02, respectively).
Discussion
The behaviour of trace elements received scarce
attention until the 1970s, when dialysis dementia
was found to be closely related to a rise in
aluminium concentration [2, 7, 13]. Contaminated
water and aluminium-containing antacids or
phosphate binders were two important sources of
aluminium accumulation in these patients [32].
Some kinetic studies showed the release of some
Figure 1. Comparision of the serum aluminium levels
between haemodialysis patients and healthy
controls. Columns represent mean ± SD
p < 0.001
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Figure 2. Comparision of the serum lead levels
between haemodialysis patients and healthy
controls. Columns represent mean ± SD
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Variable Male Female Value of p
No. 22 21 NS
Age [years] 11.95 ±3.65 10.04 ±2.91 NS
Dialysis duration [years] 3.31 ±1.51 2.51 ±1.31 NS
Aluminium [µg/l] 19.05 ±5.29 17.80 ±3.35 NS
Lead [µg/l] 38.50 ±7.61 30.13 ±10.05 < 0.04*
Data are reported as means ± SD. Significance was estimated using independent t-test,*p was significant if < 0.05
Table III. Comparison of clinical characteristics and serum aluminium and lead levels between male and female
patients with end stage renal disease
Aluminium
r  Value of p
Lead 0.75 0.0001*
Correlation was performed by Pearson’s analysis. Significant *p < 0.01
Table IV. Correlation between serum aluminium and
lead levels among HD patients
p < 0.001
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trace elements, from disposable dialysis coils and
Kiil dialysers [33-35]. Of these investigations, some
claimed that patients could accumulate or deplete
those trace elements from dialysis fluid through
different extents of protein binding [36]. The
mechanism involving abnormal metabolism of trace
metals has remained obscure.
Measurement of serum Al is made using an
atomic absorption spectrophotometer. The normal
range for serum Al as shown in this study 
(< 10 µg/l) is in general agreement with other
reports [26]. This study showed that patients on HD
Variable Aluminium Lead
r Value of pr Value of p
Age 0.23 NS 0.50 0.003**
Dialysis duration –0.07 NS 0.29 NS
Dialyser SA 0.28 NS 0.54 0.01*
Kt/V 0.09 NS –0.23 NS
Haemoglobin 0.01 NS –0.57 NS
Haematocrit [%] 0.02 NS –0.05  NS
Albumin 0.11 NS 0.45 0.03*
Serum calcium –0.003 NS –0.01 NS
Serum phosphorous –0.16 NS 0.03 NS
Serum parathormone 0.78 0.0001** 0.60 0.0001**
EPO dosage 0.77 0.0001* 0.67 0.0001*
Correlation was performed by Pearson’s analysis. Significant p < 0.05 or **p < 0.01
Table V. Correlation of serum aluminium and lead levels with different variables in HD patients
Variables β Value of p
Dependent variables, Al 
Age 0.01 NS
Haemoglobin 0.04 NS
Parathormone 0.34 0.05*
EPO dosage 0.45 0.03*
Dependent variables, Pb 
Age 0.56 0.007*
Haemoglobin –0.01 NS
Parathormone 0.35 0.05*
EPO dosage 0.45 0.04*
* p < 0.05 was considered significant
Table VI. Multiple linear regression analysis comparing
the correlation of Al and lead levels with individual
variables in serum of haemodialysis patients
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Figure 3. Scatter plot of Al vs. PTH
r = 0.78,  p = 0.0001
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Figure 4. Scatter plot of Pb vs. PTH
r = 0.60, p = 0.0001
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Figure 5. Scatter plot of EPO dosage vs. Al
r = 0.77, p = 0.0001
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had elevated serum Al levels compared to normal
controls. Although none of the patients on HD were
on AlOH3 therapy, they had Al ranging up to 
30 µg/l, well above the normal range, but within
the permissible non-toxic limits [31]. None of the
patients had toxic levels of Al in the serum 
(> 100 µg/l) [31]. Use of cooking utensils and food
habits of the patients on HD were probably similar
to the control subjects and such factors are unlikely
therefore to explain the raised serum Al levels in
the HD patients. The water source could have
contributed to the elevated levels of serum Al in
these patients [31]. Aluminium toxicity in uraemia
is well documented. Absorption from acidic and
inappropriately treated dialysis solutions is one of
the major sources of Al toxicity [37]. Some
researchers have found that Al will move into serum
if the concentration in the dialysis solution is higher
than 14 µg/l [36, 37]. At present, most Al comes
from the diet, and more importantly from
phosphate binders [37]. Aluminium intake from
phosphate binders should be deliberately
considered. Robertson [15] reported that older
patients and those for longer duration (> 5 years)
on HD are at a higher risk for Al toxicity.
In our results, the blood lead levels were
significantly higher, almost thrice that of the
control group in ESRD patients. Lead poisoning may
remain asymptomatic for many years. Major forms
of lead poisoning are lead colic, hypertension, and
neuropathy. On the other hand, minor symptoms
are common and variable: cramps, paraesthesia,
intermittent pain in the limbs, chronic abdominal
pain, and functional digestive disturbances. It is
not easy to define these symptoms in patients
with ESRD because uraemia itself may cause
and/or aggravate these symptoms. Furthermore,
chronic lead poisoning may be a cause of ESRD
[38]. As the use of unleaded gasoline becomes
more and more popular, and the use of Pb solder
in canned food and plumbing is decreased, Pb
levels are expected to decline gradually. The water
used in dialysis may be the source of the elevated
level of serum lead [39].
In this study, male patients on HD had a higher
blood lead level than did females. This is in
agreement with Rose et al. [35], who assumed that
sex hormones altered the protein binding of trace
elements during dialysis. However, the study done
by Hsu et al. [40] on a larger sample size showed
that females rather than males had higher levels of
plasma copper, blood lead, and blood mercury.
External sources may play a role in addition to sex
hormone binding.
Interestingly, we noted a strong relationship
between serum Al and serum Pb levels. This
indicates that both of these elements may share
some common absorption, transport, and tissue
distribution pathways. To what extent their ionic
radii might also play a role in this relationship is
worth considering as well [40]. These findings may
offer interesting perspectives for future studies.
In this study, serum lead accumulated with age,
but not with dialysis duration. We hypothesize that
age-dependent alteration in gastrointestinal (GI)
absorption, or bone resorption, more so than
haemodialysis itself, contributes to lead
accumulation in haemodialysis patients. One
hypothesis for such an event is that patients
surviving longer may be exposed to an environment
or diet with a high lead content [38]. Though
plasma or whole blood levels of trace metals cannot
represent their tissue accumulation [3, 17], Hsu et
al. [40] showed that clinical manifestation of these
metals correlates well with the plasma or blood
concentration. Trace metal intoxication, such as by
cadmium or aluminium, is likely responsible for
refractory anaemia [40]; therefore, the source of
contamination should be identified and removed.
Possible routes of contamination in Taiwan are
industrially polluted environments and diets, as well
as medications such as herbal drugs [40].
In the present study, no correlations were found
between TEs concentration and the duration of HD
treatment. Hsieh et al. [41] found that the duration
of HD did not affect the concentrations of TEs
except for nickel, which had a positive correlation
with the HD duration. Also, Huang et al. [38] found
that the concentrations of TEs were not affected by
the duration of chronic ambulatory peritoneal
dialysis (CAPD).
This study revealed a positive correlation
between serum lead levels among HD patients and
the dialyser surface area. Our finding is consistent
with those of a previous report, in which lead was
reabsorbed from the dialysis solution. D'Haese and
De Broe [42] found that decreased renal excretion
resulted in increased plasma TE levels in HD
patients.
In this study a positive correlation was found
between serum lead levels and serum albumin
levels. A positive correlation between serum levels
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Figure 6. Scatter plot of EPO dosage vs. Pb
r = 0.67, p = 0.0001
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of lead and protein has been found in haemo  -
dialysed patients: that is, correlation of serum lead
with total protein and prealbumin [41], and an
increase in total protein and albumin during
a haemodialysis session [40]. In uraemic children
maintained on CAPD, a positive correlation was
found between serum levels of lead and albumin
[38]. In serum, lead is bound to circulating proteins,
especially to a2-macroglobulin. Protein losses can
diminish serum lead concentration. In proteinuric
renal diseases, a negative correlation between
serum lead level and urinary protein losses was
observed, indicating that lead losses in urine were
associated with protein losses [41].
The present study showed that serum
parathyroid hormone levels positively correlated
with the serum Al levels, thereby signifying more
osteitis following maintenance haemodialysis,
which potentiates aluminium deposition in bones
and is a risk factor for osteitis fibrosa [43]. Aside
from Al, this study also showed a positive
correlation between serum parathyroid hormone
levels and serum lead levels. In previous studies,
Douthat et al. [45] had reported that chronic renal
failure or dialysis treatment per se does not lead to
bone lead accumulation. In view of this and not
withstanding that some pathology of lead on the
skeleton has been hypothesized [44], increased
bone lead concentrations most probably occur
secondary to the presence of osteomalacia. Indeed,
in contrast to an intact bone metabolism, removal
of the element from this site by deposition of new
material [45] occurs at a much lower rate in the
presence of osteomalacia. We propose that ideally
PTH levels should be maintained between 10 pmol/l
(100 pg/ml) and 20 pg/ml to 30 pmol/l (200 pg/ml
to 300 pg/ml) in chronic dialysis patients, levels two
to 4 times the upper limit of values found in normal
subjects.
This study showed that the serum levels of both
Al and Pb are positively correlated with the EPO
dose taken by the patients. There was no
relationship between the serum levels of TEs tested
and any of the other medications that the HD
patients were maintained on. Recombinant human
erythropoietin (rHuEPO) has transformed the
management of chronic renal failure and
considerably improved the outcome of patients on
regular chronic dialysis. However, a significant
number of patients fail to respond to high doses of
erythropoiesis-stimulating agents (ESAs) and several
causes of inadequate response to epoetin therapy
have been identified. Some factors, such as gender,
age, length of time on dialysis, type of dialysis and
co-morbidities such as haemoglobinopathy, are not
susceptible to clinical intervention. However, many
other factors can be adjusted. Iron deficiency is the
most common factor that limits the response to
rHuEPO. Monitoring of iron parameters and a large
use of iron supplementation result in an efficient
epoetin response. Infection and inflammation have
been shown to reduce responsiveness to ESAs by
disrupting iron metabolism and increasing the
release of pro-inflammatory cytokines that inhibit
erythropoiesis. Increased dialysis dose is associated
with improvements in anaemia correction and
reduced requirements for ESAs. Severe hyper  -
parathyroidism and aluminium overload lead to
a reduced number of responsive erythroid
progenitor cells [45]. Aluminium overload, like lead
overload, does indeed depress haematopoiesis and
has an inhibitory effect on several enzymes
important in erythroid and iron metabolism in
dialysis patients, but the severity of the anaemia
and microcytosis depends on the degree of the
aluminium overload [45, 46]. Optimizing patient
response to ESAs therefore requires consideration
of many well-established factors and is important
for both patient outcomes and cost of treatment.
There were some limitations in this study. The
sample size of patients was small, as only one
centre was included in the study. The design of our
study does not enable us to discuss the role of lead
overload in the onset of ESRD. Determination of
such a relationship would require epidemiological
studies conducted according to rigorous metho  -
dology. We cannot measure the bone aluminium
content due to the invasive bone marrow aspirate
and bone biopsy.
In conclusions, the levels of Al and Pb in blood
samples of patients on dialysis were found to be
higher than in the control group. Moreover, the
study showed that analysing levels of Al and Pb
may be useful in haemodialysis patients in
evaluating TE status. The blood level of trace metals
of these HD patients was not related to their
medications except for the EPO dose. However,
caution must be exercised in interpreting this result
as dose and duration of medication, efficiency of
HD and water treatment may play an important
role. Otherwise, environmental factors, diet, and
the aging process may contribute to the trace metal
burden in uraemia. Al and Pb overload may be
considered among the causes of inadequate
response to epoetin therapy.
In conclusion, we would like to present the
recommendations:
1. To prevent some complications in chronic HD
patients, it is very important to regulate the levels
of trace elements by adequate water treatment.
Reverse osmosis is able to prevent the
accumulation of the majority of trace elements
in the patients. Correction of Al and Pb levels may
help in optimizing patient response to epoetin
therapy. 
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2. Further investigations should be made to assess
the possible sources of aluminium and lead that
may lead to toxicity in such patients by analysing
the dialysate fluid in order to identify the possible
source of contamination.
3. Further study for determination of toxic metals
in biological samples of human beings such as
scalp hair samples is an important clinical
screening procedure. 
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